Fig. 1: BAK partial activation status varies among ovarian cancer cell lines.
From: Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer
a–f CHAPS lysates of ovarian cancer cell lines HO8910 (a), OVCAR5 (b), OVISE (c), DOV13 (d), HeyA8 (e), PA1 (f), and OV90 (g) were immunoprecipitated (IP) with antibodies to BCLXL, MCL1, or BCL2, and compared with serial dilutions of the input. IPs with normal rabbit IgG served as negative controls. *, heavy chain. h Classification of BAK partial activation status of the ovarian cancer cell lines according to the IP results. BAK status was defined as BAK bound to MCL1 only (BAK/MCL1, in orange), BAK bound to BCLXL only (BAK/BCLXL, in blue), BAK bound to MCL1 and BCLXL (BAK/MCL1 + BAK/BCLXL, in red), and BAK not bound to any indicated antiapoptotic BCL2 proteins (None, in green), respectively. The boundary-value to define BAK as partially activated was set as 5% of total cellular BAK bound to BCL2, BCLXL, or MCL1.
